Press Release
Mission ShakthiSAT Mascot Unveiled at BRICS CCI WE Summit 2026 – A Global Call for Inclusive Space Collaboration Led by India
India, 1st Apr 2026, – New Delhi – In a landmark moment for global cooperation in space science and women-led innovation, the mascot of Mission ShakthiSAT was officially unveiled at the BRICS Chamber of Commerce & Industry Women Empowerment (BRICS CCI WE) Annual Summit 2026 in New Delhi. The unveiling, graced by Ms. Meenakshi Lekhi, Former Minister of State for External Affairs, along with Ms. Ruby Sinha, President BRICS CCI WE, ambassadors, and delegates from BRICS and partner nations, marked a powerful convergence of diplomacy, science, and gender inclusion.
Adding to this moment of recognition and impact, Dr. Srimathy Kesan, Founder & CEO of Space Kidz India and Mission Director of ShakthiSAT, was honoured with the prestigious “Changemaker of the Year” Award by BRICS CCI WE. She expressed that this recognition is a great honour and a reflection of the collective efforts of young girls, global partners, and supporters who are driving meaningful change through space science and education.
The Shakthi mascot, conceptualised by Dr. Srimathy Kesan, with design execution by artist Bikram Dutt and apparel design by Ms. Harsha (Hashtag), stands as a symbol of strength, UNITY, and the transformative potential of the girl child in shaping the future of space exploration. The 108 flags on the shirt of the mascot represent the 108 participating countries in the mission.This mascot will be carried to the MOON With the 108 Country flags. “ONE UNIVERSE ONE FAMILY”
Rooted in the timeless Indian philosophy of “Vasudhaiva Kutumbakam” — the world is one family, Mission ShakthiSAT is a bold global initiative led by Space Kidz India under the leadership of Dr. Srimathy Kesan. The mission aims to empower 12,000 girls from 108 countries through intensive, hands-on training in STEM, satellite engineering, coding, and space systems. Over the course of the program, students undergo extensive hours of structured learning, technical workshops, and collaborative design processes, ensuring that participation goes beyond inspiration to real, measurable skill-building and scientific contribution.
Mission ShakthiSAT is envisioned as the world’s first all-girls international lunar mission, comprising both a Low Earth Orbit (LEO) satellite as a technology demonstrator and a lunar satellite targeting a hard landing on the Moon. This mission is not only a technological endeavor but also a global platform for scientific collaboration, enabling students from diverse geographies to work together on experiments that address real-world challenges. It reflects a shift in the global space paradigm—from isolated missions and duplication of effort to shared knowledge, collective innovation, and responsible use of space resources.
India’s leadership in this initiative underscores its evolving role as a unifying force in the global space ecosystem. By bringing together nations—large and small—Mission ShakthiSAT ensures that access to space is not limited by geography or economic status. The mission seeks to build an inclusive international framework where countries collaborate rather than compete, and where young girls are empowered to lead scientific discovery. In this spirit, the team also looks forward to meaningful engagement with global leadership, including a potential interaction with the Honorable Prime Minister of India, to further strengthen the mission’s vision and impact on a national and international scale.
The unveiling at the BRICS CCI WE Summit aligns with the theme “Women in Innovation, Science & Entrepreneurship (WISE) – Inspiring Change, Shaping Tomorrow,” reinforcing the importance of women’s leadership in shaping future economies and technologies. Mission ShakthiSAT embodies this vision by creating pathways for girls to actively participate in high-impact scientific missions while fostering international cooperation across BRICS+ and partner nations.
Building on the success of previous initiatives such as AzaadiSAT, where 750 rural Indian girls contributed to the development and successful launch of a satellite, Mission ShakthiSAT expands this model globally. It demonstrates that talent exists universally, and that with the right opportunities, mentorship, and access, young minds can contribute meaningfully to advanced scientific and technological missions.
The mission is now entering a critical phase, with selected students from participating countries expected to travel to India for hands-on payload integration, testing, and ground station development, followed by launch preparations.
The international student program and travel to India is scheduled from August 23 to September 1, 2026, during which participants will engage in intensive hands-on training, collaboration, and mission integration activities.
As the mission progresses toward its orbital and lunar milestones, Space Kidz India is actively engaging with global institutions, industry leaders, and stakeholders to build strong support systems and partnerships.
Mission ShakthiSAT is currently seeking CSR partners and institutional collaborators to support this historic initiative. Organizations aligned with the vision of inclusive growth, STEM education, and global cooperation are invited to partner in enabling access, infrastructure, training, and mission development—ensuring that this transformative opportunity reaches deserving girls across the world.
Mission ShakthiSAT is supported by a strong ecosystem of partners and collaborators who have stood by the initiative and contributed to its growth and impact. The team extends its sincere gratitude to IN-SPACe, ISRO, Hexaware, Ananth Technologies, Zoho Learn, AIMERS Foundation, Meridien Space Command, BCI Aerospace, World Space Week Association, and several other global and regional partners, whose continued support has been instrumental in advancing the mission’s goals.
The Shakthi mascot represents more than a mission—it represents a movement. A movement where a girl from any part of the world can build, innovate, and lead in space science. A movement where nations come together not in competition, but in collaboration. And a movement where space becomes a shared platform for peace, progress, and collective human advancement.
Space Kidz India, the organization behind this initiative, has established itself as a pioneer in student-led space missions, having launched over 20 balloon satellites, 3 suborbital satellites, 5 orbital satellites, and 2 rocket launches, while inspiring thousands of students through hands-on international exposure and training. With Mission ShakthiSAT, the organization takes a significant step forward in scaling its vision globally, positioning India at the forefront of a new era in space exploration defined by inclusion, collaboration, and purpose.
Source : https://apnews.com/press-release/getnews/mission-shakthisat-mascot-unveiled-at-brics-cci-we-summit-2026-a-global-call-for-inclusive-space-collaboration-led-by-india-519ada8ecc142b015a59399e61df5f6f
Media Contact
Organization: Space Kidz India
Contact
Person: Dr. Srimathy Kesan, Founder and CEO
Website:
https://www.spacekidzindia.in
Email:
spacekidzindia@gmail.com
Contact Number: 919962833622
Country:India
The post
Mission ShakthiSAT Mascot Unveiled at BRICS CCI WE Summit 2026 – A Global Call for Inclusive Space Collaboration Led by India appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s technological approach, clinical trial progress, global strategic expansion — particularly in China and India — financing status, and deep insights into the global biotechnology industry.
1. Company Overview & Core Technology
Company Background
CytoMed is a clinical-stage biotech spin-off from ASTAR, Singapore’s national scientific research agency. The company focuses on developing affordable cancer therapy using patented allogeneic Gamma Delta T Cells derived from healthy donors.
Mission
The company aims to address the major limitations of existing cell therapies such as CAR-T, including high treatment costs and lengthy manufacturing timelines. By using blood from healthy donors to manufacture “off-the-shelf” immune cells, the company aims to reduce production costs and enable global distribution.
Technological Advantages
Safety
Gamma Delta T Cells have a lower risk of causing Graft-versus-Host Disease (GVHD), making them suitable for allogeneic transplantation.
Versatility
The cells express CARs (Chimeric Antigen Receptors) targeting NKG2D ligands, enabling recognition of multiple cancer types that express stress-related molecules, including Solid tumors & Hematological malignancies.
2. Clinical Trial Progress
Singapore ANGELICA Trial
Nature of the Trial
Ongoing first-in-human clinical trial targeting patients with:
Advanced solid tumors
Hematological malignancies
Progress
The trial comprised 12 patients in total, and treatment has been completed for half of the participants (6 patients).
Objective
To complete the Phase 1 clinical trial and evaluate before embarking on Phase 2 by next year 2027:
Safety
Efficacy of the CAR-modified version
Malaysia Clinical Trial
Strategy
CytoMed plans to launch a first-in-human clinical trial for the unmodified version of the therapy, which is expected to be significantly less expensive than the CAR-T version.
Collaboration
The company is collaborating with Universiti Malaya Hospital and is preparing to submit trial documentation to regulators and start by this year 2026.
3. Strategic Expansion & Acquisitions
Acquisition of TC BioPharm (UK)
Through this acquisition, CytoMed obtained feeder-free manufacturing technology, solving logistical challenges associated with cross-border transportation of specialized feeder cells and strengthening its cancer therapy platform.
Acquisition of Longevity Bank (Malaysia)
Background
In mid-2024, CytoMed acquired a Malaysian cord blood bank that had entered liquidation due to the impact of the pandemic. The bank had approximately 12,000 customers.
Strategic Purpose
The acquisition provides access to cord blood resources for the development of Natural Killer (NK) Cell therapies from pristine cord blood.
NK cells have potential applications in:
Anti-aging
Elimination of senescent cells
This acquisition also broadens the company’s therapeutic pipeline.
4. Global Market Strategy: Focus on China & India
China (Key Strategic Focus)
Policy Opportunity
CytoMed is closely monitoring China’s “Directive 818,” which allows hospitals conducting investigator-initiated trials (IITs) to charge patients, thereby helping subsidize biotechnology companies’ R&D and manufacturing costs.
Competitive Advantage
Compared with the capital-intensive “cash-burning” model commonly seen in Western biotech companies, the Chinese model is viewed as more sustainable.
China’s Government-backed biotech parks, Pragmatic regulatory policies & Strong venture capital ecosystem have made the country highly attractive for biotechnology development.
Market Potential
China has a massive cancer patient population and regulatory flexibility for compassionate-use style commercialization making it a critical strategic market for CytoMed.
India
As one of the world’s two largest population centres, India is also a major target market for the company.
United States
Although CytoMed collaborates with MD Anderson Cancer Center — where animal studies showed effectiveness against AML — the company currently does not prioritize the U.S. market due to the long time and extremely high cost of clinical trials.
5. Financial Position & Industry Perspectives
Financial Status
The company raised only USD 8 million during its 2023 IPO due to difficult biotech market conditions at the time.
However, management has maintained disciplined spending while seeking partners to co-develop its proprietary allogeneic cancer technologies.
View on the “Biotech Winter”
The Chairman believes the biotech industry is currently experiencing a “winter” caused by:
Excessively high valuations during the pandemic era
SPAC-related speculation
Significant investor losses
Tightening capital markets
The company also faces:
Heavy short-selling pressure
Interference from day traders
Strategic Pivot
To survive the difficult funding environment, CytoMed is shifting toward closer collaboration with hospitals to provide treatments for “no-option” patients.
The company benefits from low cost infrastructure in Southeast Asia and aims to:
Attract international medical tourists
Leverage Malaysia’s “Medical Tourism Year 2026”
Generate revenue while simultaneously collecting clinical data
6. Regulatory Advocacy
Compassionate Use
CytoMed advocates for regulators to adopt a more flexible approach for terminal patients who have exhausted all available treatment options, allowing access to new cell therapies.
East-West Differences
The Chairman noted that Eastern societies, particularly in Southeast Asia, generally have less aggressive litigation cultures compared with Western countries such as the United States.
This creates a more favourable environment for Compassionate Use programs, allowing terminal patients to try innovative therapies when conventional options have failed.
Conclusion
The interview highlights CytoMed’s unique “low-cost survival strategy” within the highly expensive biotechnology sector.
By leveraging:
Southeast Asia’s lower manufacturing and labour costs
Strategic hospital partnerships
China’s “Directive 818” policy framework
the company has identified a pragmatic commercialization pathway during the ongoing biotech capital winter.
CytoMed’s approach demonstrates not only technological ambition, but also strong strategic insight into the evolving global biotechnology landscape.
Media Contact:
Media Relations
CytoMed Therapeutics Ltd
Singapore
https://www.cytomed.sg/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
LingSense Bio Debuts in Silicon Valley With Advanced CGM & Wearable Dynamic Blood Pressure Technology
While the global digital health industry remains focused on specification-driven competition and fragmented use cases, LingSense Bio, a rising Chinese medtech innovator, chose Silicon Valley as the stage to present its answer.
At the “BEYOND SLEEP: THE STAREEP PREMIERE” global launch event, LingSense Bio, official medical health partner of smart sleep brand Stareep, made its international debut, introducing a comprehensive, closed-loop health management solution that integrates hardware, software, and AI services. This innovation aims to redefine healthcare standards for billions of chronic disease patients worldwide.
LingSense Bio’s wearable product lineup made a stunning debut
The LingSense Bio Ecosystem Ushers in an All in One AI Era of Seamless Monitoring
With the global chronic disease management market expanding rapidly into a trillion-dollar industry, Faris Li, Head of Product at LingSense Bio, delivered a keynote speech titled “Redefining Health Monitoring with Healthcare AI Wearables.” His assessment was direct: “Hardware alone cannot solve the challenges of chronic disease management. Without AI-driven intervention, health data is just a pile of numbers.”
Faris highlighted that while over 626 million people suffer from cardiovascular diseases and 830 million live with diabetes globally, continuous glucose monitoring (CGM) penetration among type 2 diabetes patients remains below 10%. Furthermore, dynamic blood pressure monitoring has long been constrained by traditional cuff-based devices. “Patients need unobtrusive, continuous, and precise monitoring, not fragmented occasional readings,” Faris emphasized. The future of medical-grade wearables, he noted, lies in two key trends: multi-parameter “All-in-One” integration and deep AI embedding from edge to platform.
To address these needs, LingSense Bio has developed a product matrix. Faris Li showcased two groundbreaking core hardware innovations:
Continuous Glucose Monitor (CGM): Boasting an industry-leading MARD (Mean Absolute Relative Difference) of under 8.0%, rivaling top-tier global brands.
Wearable dynamic Blood Pressure Monitor (dBP): The world’s first wearable dBP powered by Tonoarteriography (TAG) technology, developed by Professor Yuan-Ting Zhang’s team, delivering medical-grade continuous blood pressure tracking.
LingSense Bio also introduced LingWatch Pro, a smart watch with dynamic blood pressure monitoring; LingRing Nexus R1, a smart ring integrating non-invasive blood glucose trend monitoring, PPG, blood oxygen, temperature, and heart rate variability (HRV) monitoring; and LingCare SpringMini, a portable oxygen concentrator designed to provide stable oxygen supply at altitudes of up to 6,000 meters.
These devices function as specialized physiological sensors that stream data into the LingSense Chronic Disease Management Platform, forming a closed-loop ecosystem covering glucose, blood pressure, blood oxygen, and ECG.
Faris Li delivered a keynote speech titled “Redefining Health Monitoring with Healthcare AI Wearables.”
Professor Yuan-Ting Zhang: Three Decades of Cuffless Innovation Reach Industrial Standard Moment
At the event, Professor Yuan-Ting Zhang, a Fellow of the International Academy for Medical and Biological Engineering, delivered a presentation titled “AI-Empowered Tonoarteriography for Digital Cardiovascular Health.” With over 30 years of pioneering research in cuffless blood pressure monitoring, Academician Zhang shared clinical insights and engineering philosophies that underscore the team’s forward-looking approach to digital cardiovascular health.
Professor Zhang pointed out that traditional blood pressure monitoring fails to capture critical nocturnal data. Clinical follow-ups from the Dublin Hypertension Clinic show that nighttime hypertension is highly correlated with a 5-year risk of cardiovascular mortality, and increased blood pressure variability serves as an independent warning sign. “However, traditional cuff-based devices cannot frequently inflate while a patient is sleeping without disrupting their rest,” Professor Zhang noted, highlighting the necessity of cuffless wearable technology. The deep learning models developed by his team for systolic and diastolic measurements have already achieved Grade A performance under IEEE, AAMI, and BHS standards.
Professor Yuan-Ting Zhang delivered a presentation titled “AI-Empowered Tonoarteriography for Digital Cardiovascular Health.”
The “dBP” solution represents a new era of 24/7 health management. By fusing physiological sensing, intelligent algorithms, and continuous data analysis, it offers a natural, low-burden monitoring experience. “The dBP focuses on long-term health trends rather than isolated readings,” Professor Zhang explained. “By analyzing continuous data streams, the system can provide valuable clinical insights for diagnosing masked hypertension, nocturnal anomalies, and evaluating chronic disease risks.”
Notably, Daniel Franklin, an Assistant Professor in the Institute of Biomedical Engineering at the University of Toronto, traveled to Silicon Valley as a specially invited international guest for the event. He participated in a session themed “Technology & Healthy Sleep,” where he engaged in an in-depth academic dialogue with fellow attendees. Known for his work in bio-integrated electronics and soft-matter photonics, Franklin offered an independent, clinically informed perspective on the event’s most anticipated innovation, the wearable dynamic blood pressure (dBP) monitoring technology.
Daniel Franklin participated in a session themed “Technology & Healthy Sleep” and shared in-depth academic insights
Data from LingSense Bio’s wearable product matrix, including CGM readings, ambulatory blood pressure data, blood oxygen saturation, and ECG signals, will be synchronized in real time to the LingSense Chronic Disease Management Platform. Built on LingSense Bio’s self-developed, medical-grade AI large model, the platform analyzes continuous health data and identifies potential risk patterns. It further incorporates Dr. PAI (Personalized AI Doctor), the world’s first hypertension intelligent management platform that combines a wearable dynamic blood pressure monitoring device, an AI health assistant avatar, and a large language model, developed by the team led by Professor Zhang. Together, they deliver a closed-loop experience spanning AI-powered consultation, health assessment, blood pressure pattern recognition, and personalized health management recommendations.
In January 2026, the U.S. Food and Drug Administration (FDA) officially released the draft guidance titled “Cuffless Non-invasive Blood Pressure Measuring Devices – Clinical Performance Testing and Evaluation,” marking a long-awaited standard for the industrialization of a technology nearly three decades in the making. Professor Zhang’s team has been deeply involved in the development of both the FDA draft guidance and the relevant IEEE standard; the IEEE standard led by his team has already been adopted by the FDA as a reference. “The world is embracing this standard, and LingSense is ready to be tested,” Professor Zhang said.
A China-Born Solution for Global Standards
As the Silicon Valley sun cast its glow over Stanford, LingSense Bio’s brand logo lit up across the giant screen. Without complicated regulatory language or excessive marketing rhetoric, LingSense had already delivered its message: connecting China’s precision with the world’s broader healthcare needs.
From CGM systems with an MARD below 8.0% to the medical-grade continuous wearable blood pressure monitor dBP, LingSense Bio is challenging a market long dominated by industry giants like Dexcom and Abbott. But for chronic disease patients around the world, the most meaningful takeaway from this launch may be what LingSense Bio President Zhifeng Peng put most simply: “Whether you live in a major city or a remote village, expert-level personal healthcare should not be a privilege.” This China-born solution, making its debut in Silicon Valley, is now accelerating onto the global stage.
Media Contact
Organization: LingSense Bio (Shenzhen) Technology Co., Ltd.
Contact Person: Ying Jixuan (Nancy)
Website: https://en.lingshee.com
Email:
yingjixuan@dreame.tech
City: Shanghai
Country:China
Release id:45276
The post LingSense Bio Debuts in Silicon Valley With Advanced CGM & Wearable Dynamic Blood Pressure Technology appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
SINGAPORE — Integrated Learning Systems (ILS), a leading provider of corporate training and development solutions, has announced the launch of its updated Team Alignment Workshop, designed to help organisations close the growing gap between team potential and business performance. Many organisations today struggle with misaligned leadership teams, siloed teams, and poor cross‑functional collaboration, creating internal friction that directly hurts performance and execution speed.
Singapore, 21st May 2026 — Integrated Learning Systems (ILS), a leading provider of corporate training and development solutions in Singapore, has announced the launch of its updated Team Alignment Workshop, designed to help organisations close the growing gap between team potential and business performance. Many organisations today struggle with misaligned leadership teams, siloed teams, and poor cross‑functional collaboration, creating internal friction that directly hurts performance and execution speed.
ILS was awarded the Silver honour in the “Best Management Training Provider” category at the prestigious HR Vendors of the Year 2025 Awards ceremony held in Singapore on 7 November 2025, a testament to the trust of its clients and its commitment to driving leadership growth and performance excellence.
“Team alignment is not just about working well together. It is about moving in the same direction with clarity, purpose, and shared accountability,” said Jessica Choo, Founder and Chief Strategist of ILS, who brings over 30 years of consulting experience to the programme.
She added that when leadership teams are not aligned, even strong individual performers can become trapped in silos, decisions slow down, accountability erodes, and internal friction begins to hurt performance. “When teams are truly aligned, organisations become far more resilient and competitive.”
The updated workshop is built around five core alignment pillars. These pillars directly address the root causes of siloed teams, unclear roles and ownership, and internal friction that undermine collaboration across functions.
- Shared Purpose & Direction — Establishing a unified understanding of team goals and how they connect to organisational strategy
- Trust & Psychological Safety — Creating an environment where team members can speak up, take risks, and collaborate openly
- Roles & Accountability Clarity — Defining clear ownership so teams execute with confidence and minimal friction
- Communication & Conflict Fluency — Building the skills to navigate difficult conversations and disagreements constructively
- Agility & Collective Problem Solving — Developing the team’s ability to adapt, respond, and innovate together under pressure
The workshop is facilitated by ILS master trainers including Jessica Choo and Linda Tan-Spicer, Lead Development Strategist with over 20 years of experience in performance strategy and behavioural change.
“We’ve completely refreshed this workshop to address the real challenges teams face today,” said Linda Tan-Spicer.“We focus on changing everyday team behaviours. How decisions are made, how conflict is handled, and how accountability is enforced in reality, not in theory,”
The Team Alignment Workshop is targeted at corporate leaders, team managers, and cross-functional groups across industries in Singapore, as well as global organisations seeking to strengthen collaboration, reduce friction, and accelerate team performance. It is particularly relevant for organisations experiencing persistent cross‑team friction, inconsistent leadership direction, or breakdowns in collaboration that impact business results.
For more information on the Team Alignment Workshop in Singapore or to register, contact ILS at +65 9745 5771 or visit their website.
About Integrated Learning Systems (ILS)
Integrated Learning Systems (ILS) specialises in corporate training and development with a focus on team performance, leadership growth, and building future-ready organisations. With over 1,000 corporate clients served, ILS has empowered more than 150,000 learners across Asia, the Middle East and Europe.
Media Contact
Organization: Integrated Learning Systems (ILS)
Contact Person: Jonathan Tan
Website: https://ilsperformance.com
Email: Send Email
Contact Number: +6597455771
Address:9 Tampines Grande
Address 2: #02-00 Asia Green, Singapore 528735
City: Singapore
Country:Singapore
Release id:45262
The post Team Alignment Workshop in Singapore launched by Integrated Learning Systems appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
CytoMed Therapeutics Ltd — A Rising Star in Singapore’s Cancer Biotechnology Sector
LingSense Bio Debuts in Silicon Valley With Advanced CGM & Wearable Dynamic Blood Pressure Technology
Team Alignment Workshop in Singapore launched by Integrated Learning Systems
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release3 days ago
Community Rallies Around Tracey Archer Family Following Sudden Loss of Noah Thomas Archer
-
Press Release3 days ago
PortaProfits Releases Transparency Report: 30+ Partner Reviews Now Public
-
Press Release1 week ago
CEMOTO D series Electric Dirt Bike: Redefining Off-Road Adventure with Zero-Emission Power
-
Press Release5 days ago
King VPN Offers 100+ Free VPN Locations for USA Users
-
Press Release5 days ago
Prime VPN: A Fast and Simple VPN App for UK Users with 70+ Free VPN locations
-
Press Release5 days ago
Secure VPN Announces 50+ Free VPN Locations for US Android Users
-
Press Release5 days ago
Readers Favorite announces the review of the Non-Fiction – Memoir book A Past That Lies Before Me by Steve Clark, PhD
-
Press Release5 days ago
Readers Favorite announces the review of the Non-Fiction – Memoir book A Past That Lies Before Me by Steve Clark, PhD